

# Report from Industry Scientific Advisory Board

PPMI Annual Investigators Meeting  
May 4-5, 2011

Igor Grachev, MD, PhD



PARKINSON'S  
PROGRESSION  
MARKERS  
INITIATIVE

Play a Part in Parkinson's Research



# ISAB Update


- What is ISAB?
- Who we are?
  - Chair: Igor Grachev, GE Healthcare
  - Kim Gallagher, GE Healthcare (secondary representative)
  - Michelle Collins, Abbot
  - Tom Comery, Pfizer
  - Susanne Ostrowizki, Roche (primary representative)
  - Paulo Fontoura, Roche (secondary representative)
  - Johan Luthman, Merck (primary representative)
  - Tony Ho, Merck (secondary representative)
  - Marcel van der Brug, Genentech
  - Bernard Ravina, Biogen Idec
- Stakeholder role of the ISAB
  - Strategic arm of Steering Committee
  - Input in Taskforces/Working groups
  - Participate in Annual Meeting and bi-monthly t-cons
  - Support Steering Committee
  - Suggest Ancillary Studies
- Why industry involvement is important and next steps?



PARKINSON'S  
PROGRESSION  
MARKERS  
INITIATIVE



# PPMI Study Organization and Governance



PARKINSON'S  
PROGRESSION  
MARKERS  
INITIATIVE

Play a Part in Parkinson's Research

# Stakeholder Role of ISAB

- ISAB plays a critical role in providing input and strategic advice on study parameters and goals
- All partner companies can have one primary designate and one secondary designate (to fill in when the primary cannot attend) to the ISAB
- ISAB Chairmanship will rotate on an annual basis; Chairs are to be selected by the ISAB
  - 1<sup>st</sup> Chair – GE Healthcare as first industry partner to sign up
  - 2<sup>nd</sup> Chair - Pfizer
- Acting and future chairs will participate in monthly Steering Committee calls and report back to ISAB colleagues
- Each company can assign one primary and one secondary to Taskforces/Working Groups of interest
- Each company can have two attendees at the Annual Meeting of the study
- Support Steering Committee
- Suggest Ancillary Studies



PARKINSON'S  
PROGRESSION  
MARKERS  
INITIATIVE

# ISAB Next Steps

- ISAB bi-monthly t-cons to formulate Goals and Objectives to support PPMI mission.
- Identify individuals within partner companies to integrate into taskforces/working groups. Ensure partner representation in working groups.
- Formulate and communicate ISAB members needs.
- Evaluate needs and gaps, and recommend new ancillary studies to accelerate drug development in PD, biomarkers acceptance by regulators, and develop new indications for approved products.
- Support PPMI in adding new ISAB members and in closing funding gaps.
- Finalize ISAB organization/working groups.



PARKINSON'S  
PROGRESSION  
MARKERS  
INITIATIVE

